Literature DB >> 2460508

Melanophages in inflammatory skin disease demonstrate the surface phenotype of OKM5+ antigen-presenting cells and activated macrophages.

J S Weiss1, W D James, K D Cooper.   

Abstract

Previous studies in our laboratory revealed that ultraviolet light induces the appearance of epidermal melanophages that have potent antigen-presenting ability, that can activate autoreactive T cells, and that exhibit the immunophenotype OKM5+, OKM1-, T6-, and DR+. Therefore we undertook immunophenotyping of melanophages in selected inflammatory mucocutaneous lesions to determine whether the OKM5+, OKM1- phenotype was limited to ultraviolet-induced inflammation or whether the occurrence of melanophages expressing this antigen-presenting cell phenotype was a more generalized phenomenon. Ten of the eleven patients with chronic inflammatory skin lesions demonstrated melanophages expressing the OKM5+, OKM1-, T6-, DR+ immunophenotype. In addition, they often expressed Mo3e, a marker of activated macrophages. In contrast, melanophages of a patient with post-inflammatory hyperpigmentation, although DR+, failed to express OKM5. These results are taken to support an active role for OKM5+, OKM1-, T6-, DR+ melanophages in inflammatory skin disease because these cells demonstrate the phenotype of activated inflammation-producing monocytes and potent antigen-presenting cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2460508     DOI: 10.1016/s0190-9622(88)70217-0

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  2 in total

1.  Dermal dendrocytes and photochemotherapy.

Authors:  G E Piérard; A Nikkels; J Arrese Estrada; T Ben Mosbah; C Piérard-Franchimont
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

Review 2.  Topical treatment strategies to manipulate human skin pigmentation.

Authors:  Inbal Rachmin; Stephen M Ostrowski; Qing Yu Weng; David E Fisher
Journal:  Adv Drug Deliv Rev       Date:  2020-02-21       Impact factor: 15.470

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.